{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04080245",
            "orgStudyIdInfo": {
                "id": "IRB-300003669"
            },
            "organization": {
                "fullName": "University of Alabama at Birmingham",
                "class": "OTHER"
            },
            "briefTitle": "Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)",
            "officialTitle": "Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)",
            "acronym": "LAIV",
            "therapeuticArea": [
                "Other"
            ],
            "study": "functional-consequences-of-t-bet-expression-in-flu-specific-memory-b-cells-after-live-attenuated-influenza-vaccine-laiv"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-11-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-09-03",
            "studyFirstSubmitQcDate": "2019-09-05",
            "studyFirstPostDateStruct": {
                "date": "2019-09-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Anoma Nellore",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of Alabama at Birmingham"
            },
            "leadSponsor": {
                "name": "University of Alabama at Birmingham",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "As yet the investigators do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV). Here the investigators test the hypothesis that the T-bet expressing fraction of flu-specific B cells after live attenuated influenza vaccination also serves as an early biomarker of long-lived antibody responses after vaccination. In this study the investigators will be providing the LAIV to up to 10 healthy subjects and assaying their immune response and then providing the intramuscular influenza vaccination and testing to see if the immune protection after the LAIV also protects after the intramuscular influenza vaccination.\n\nUpdate: We have amended this protocol to study the antigen-specific B cell populations that circulate after LAIV or IIV prime and LAIV or IIV boost.",
            "detailedDescription": "Previously (1) the investigators established that a fluorochrome labeled reagent with the influenza antigen hemagglutinin accurately identified flu-specific B cells after inactivated influenza vaccination and we established that a subset of these flu-specfiic B cells that express the lineage defining master transcriptional regulator, T-bet, correlate with long lived antibody responses. As yet the investigators do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV). Here the investigators test the hypothesis that the T-bet expressing fraction of flu-specific B cells after live attenuated influenza vaccination also serves as an early biomarker of long-lived antibody responses after vaccination. In this study the investigators will be providing the LAIV to up to 10 healthy subjects and assaying their immune response and then providing the intramuscular influenza vaccination and testing to see if the immune protection after the LAIV also protects after the intramuscular influenza vaccination.\n\nUpdate: We have amended this protocol to study the antigen-specific B cell populations that circulate after LAIV or IIV prime and LAIV or IIV boost."
        },
        "conditionsModule": {
            "conditions": [
                "Influenza, Human"
            ],
            "keywords": [
                "Vaccine",
                "Influenza",
                "Efficacy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment Group",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: Treatment Group Live Attenuated Flu Vaccine (LAIV)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Treatment Group Live Attenuated Flu Vaccine (LAIV)",
                    "description": "We will administer LAIV once as a vaccine prime and IIV once as a vaccine boost with serial weekly blood draws for a month to validate a biomarker of LAIV efficacy.",
                    "armGroupLabels": [
                        "Treatment Group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Outcome Measure: Participants with a positive T-bet expressing Flu-specific B cell subtype",
                    "description": "The investigators will perform a blood test on lymphocytes from circulating blood.",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Outcome Measure: Participants with a positive T-bet expressing Flu-specific B cell subtype",
                    "description": "The investigators will perform a blood test on lymphocytes from circulating blood.",
                    "timeFrame": "7 days post first injection"
                },
                {
                    "measure": "Outcome Measure: Participants with a positive T-bet expressing Flu-specific B cell subtype",
                    "description": "The investigators will perform a blood test on lymphocytes from circulating blood.",
                    "timeFrame": "14 days post first injection"
                },
                {
                    "measure": "Outcome Measure: Participants with a positive T-bet expressing Flu-specific B cell subtype",
                    "description": "The investigators will perform a blood test on lymphocytes from circulating blood.",
                    "timeFrame": "7 days post second injection"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Missed getting the flu vaccine in the last year\n* No history of reactive airway disease\n* No history of allergy to LAIV\n* No history of allergy to IIV\n* Self-identify as healthy without an immunocompromising condition defined as cancer, autoimmune disease, organ transplant or receipt of steroids.\n\nExclusion Criteria:\n\n* History of reactive airway disease\n* History of allergy to LAIV or IIV\n* Do not self-identify as healthy",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Anoma Nellore, MD",
                    "role": "CONTACT",
                    "phone": "2059345191",
                    "email": "anellore@uabmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Anoma Nellore, MD",
                    "affiliation": "University of Alabama at Birmingham",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anoma Nellore, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Anoma Nellore, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007251",
                    "term": "Influenza, Human"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012141",
                    "term": "Respiratory Tract Infections"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000009976",
                    "term": "Orthomyxoviridae Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10295",
                    "name": "Influenza, Human",
                    "asFound": "Influenza",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14978",
                    "name": "Respiratory Tract Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M12902",
                    "name": "Orthomyxoviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}